Cincinnati Childrenâ€s Cancer & Blood Diseases Institute is investing $75 million in expanding its research programs in (1) precision medicine & drug discovery, (2) cellular & immune cancer therapy, (3) advanced proton & FLASH therapy, (4) young adult oncology, and (5) next-generation care navigation. We seek dynamic and outstanding individuals at all faculty levels with a career focus in academic translational research. The Division of Oncology includes 30 academic clinical faculty – with new recruitment positions in our medical subspecialty programs including:
- Gene and Cellular Therapy & Research Center
- Leukemia/Lymphoma Center
- Sarcoma Center
- Neuroblastoma Center
- Liver/Renal Tumor Center
- Proton Therapy & Research Center
Successful applicants must be board-eligible or board-certified in Pediatric Hematology-Oncology with prior training in either Pediatrics or Medicine-Pediatrics. Strong mentorship in clinical care and the development of investigator-initiated studies will be provided, along with integration in our robust “team science†translational oncology programs in pediatric and young adult early phase studies and drug development.
Cincinnati Children's is an exceptional environment for leading-edge translational cancer research and career development. It is ranked as both the #1 pediatric cancer program and childrenâ€s hospital by US News. It has one of the largest research programs in the nation - ranking in the top 2 among pediatric institutions in funding from the National Institutes of Health. Cincinnati Childrenâ€s is an international referral center for pediatric and young adult cancer and stem cell transplantation, cellular and immune therapies, and novel anticancer drugs, and sees over 500 new & relapse patients per year. Cincinnati Children's is a member of the NCI Pediatric Early Phase Clinical Trials Network, SARC Consortium, Pediatric Brain Tumor Consortium, Department of Defense Neurofibromatosis Consortium, New Approaches to Neuroblastoma Treatment Consortium, Therapeutic Advances in Childhood Leukemia Consortium, Pediatric Bone Marrow Transplant Consortium, and select studies of the POETIC consortia.
Our team science approach led to the recent FDA pediatric approvals of the new drugs Vyxeos for acute myeloid leukemia, and selumetinib for patients with inoperable neurofibromatosis tumors. Our first-in-human FLASH proton therapy clinical trial was named one of the top 10 advances in physics for 2022.
Multiple cores support basic and translational research, including genomics, high-density data informatics/systems biology, pharmacology, mouse models of cancer, stem cell and gene/viral vector therapy, organoid medicine, and a growing cellular therapy program. Additional information can be found at:
Contact - Please email cover letter & curriculum vitae to:
John Perentesis, MD FAAP
Professor of Pediatrics, University of Cincinnati College of Medicine
Kleisinger Chair and Director of Oncology & Cancer Programs
Cincinnati Childrenâ€s Hospital Medical CenterÂ
email:
Requirements
ABP Board-eligible or board-certified in Pediatric Hematology-Oncology
Prior training with board certification in either Pediatrics or Medicine-Pediatrics
MD or DO or MBBS